Background
Unhealthy alcohol use in the hospital
Detecting and categorizing the severity of unhealthy alcohol use
Assessment for unhealthy alcohol use
Screening tool | Positive result | Sensitivity | Specificity | Study Populations |
---|---|---|---|---|
(95% CI) | (95% CI) | |||
AUDIT-C | ≥ 4 (men) | 86 (80-92) men | 89 (85-93) men | Primary care [24] |
(3 items)* | ≥ 3 (women) | 73 (66-79) women | 91 (89-93) women | |
Quantity-Frequency | Exceeding recommended | 88 (83-94) men | 84 (80-89) men | Primary care [24] |
(3 items)* | drinking limits | 68 (61-75) women | 91 (89-93) women | |
Heavy-drinking day | Any heavy days (≥ 4 drinks women, ≥ 5 drinks men) | 83 (71-90) men | 72 (61-81) men | Primary care [27] |
past year (1 item) | 81 (64-91) women | 84 (76-89) women |
Assessment for alcohol use disorders in patients with unhealthy use
Instrument | Positive result | Sensitivity | Specificity | Study populations |
---|---|---|---|---|
AUDIT | ≥ 8 | Range | Range | Systematic review of primary care studies [21] |
(10 items)* | 61 to 96 | 85 to 96 | ||
CAGE | ≥ 2 | Range | Range | Systematic review of primary care studies [21] |
(4 items) | 77 to 94 | 79 to 97 | ||
RAPS4 | ≥ 1 | 93 | 87 | Emergency department patients [40] |
(4 items) |
DSM-IV Alcohol dependence | DSM-IV Alcohol abuse | DSM-V Alcohol use disorder |
---|---|---|
(≥ 3 of the following) | (≥ 1 of the following) | (≥ 2 of the following) |
• Tolerance | Continued drinking despite…. | • Tolerance |
• Withdrawal | • Withdrawal | |
• Repeatedly exceeding intended limits | • Increased risk for physical harm | • Repeatedly exceeding intended limits |
• Spending a lot of time drinking or recovering from alcohol effects | • Trouble in important relationships | • Spending a lot of time drinking or recovering from alcohol effects |
• Failed attempts to cut down or abstain | • Failure to perform important roles | • Failed attempts to cut down or abstain |
• Continued drinking despite physical or psychological problems | • Legal problems* | • Continued drinking despite physical or psychological problems |
• Spending less time on important activities due to drinking | • Spending less time on important activities due to drinking | |
• Increased risk for physical harm | ||
• Trouble in important relationships | ||
• Failure to perform important roles | ||
• Craving for alcohol* |
Treatment for unhealthy alcohol use
Treatment for non-dependent unhealthy alcohol use
Acute Treatment for alcohol use disorders (typically accompanied by frequent heavy drinking)
Clinical issue | Treatment |
---|---|
Assess risk for nutritional deficiency | • Thiamine supplementation. |
• Possibly folate and multivitamin supplement. | |
Assess hydration status and electrolytes (risk for hypocalcemia and hypomagnesemia with or without hypokalemia and hypophosphatemia) | • IV or oral fluids. |
• Oral or IV electrolyte replacement. | |
Risk for acute alcohol withdrawal | • Close observation with validated instrument or prophylactic benzodiazepine, particularly in those with previous withdrawals or history of severe withdrawal (delirium tremens or seizure). |
• Prophylaxis still requires close observation for over or under-sedation. | |
Active alcohol withdrawal | • Symptom-triggered or scheduled benzodiazepine. |
• Close observation with validated instrument with either symptom-triggered or scheduled dosing. | |
• Alternate medication (e.g., phenobarbital) in rare event that benzodiazepine is unsuccessful at controlling agitation. | |
• Possible beta blocker or clonidine for autonomic manifestations if benzodiazepine alone is insufficient. | |
• Possible haloperidol if benzodiazepine alone is insufficient for delirium. | |
• Consider other causes of delirium. |
Initial oral medication dose | Frequency | Medication half-life |
---|---|---|
Diazepam 10 to 20 mg if CIWA-Ar ≥ 8 to 10 | Repeat same dose hourly until | Long half-life may provide smoother withdrawal, but may accumulate in elderly or those with liver disease. |
CIWA-Ar < 10 | ||
Chlordiazepoxide 50 mg if CIWA-Ar > 9 | Repeat 50 mg hourly until CIWA-Ar < 10 | Intermediate half-life may provide smoother withdrawal than lorazepam. |
Lorazepam 2 to 4 mg if CIWA-Ar ≥ 8 to 10 | Repeat same dose hourly until | Short half-life may increase withdrawal symptoms between doses. May be better tolerated in elderly and liver disease patients. |
CIWA-Ar < 10 |
Pre-operative assessment for patients with an alcohol use disorder
Additional pre-discharge treatment considerations for patients with an alcohol use disorder
Medication | Drinking Outcome | Effect estimate | Source | Factors Influencing Medication Choice |
---|---|---|---|---|
(95% CI or p-value) | ||||
Naltrexone | Heavy drinking day (≥ 60 grams alcohol) | Relative risk 0.83 | Meta-analysis of 50 | Avoid in patients with opioid abuse or use; caution in liver disease and advanced kidney disease |
(0.76-0.90) | randomized controlled trial (RCT’s) [87] | |||
Acamprosate | Any drinking | Relative risk 0.86 | Meta-analysis of 24 | Avoid with advanced kidney disease (e.g., creatinine clearance < 30 ml/min) |
(0.81-0.91) | RCT’s [86] | |||
Disulfiram | Any drinking | Slight majority of trials found improved abstinence. | Review of 11 RCT’s [85] | Avoid if alcohol-disulfiram reaction medically dangerous; number of medical conditions associated with accidental reaction; avoidance of alcohol-containing products |
Topiramate* | % heavy drinking days | 8.4% reduction | Multicenter RCT [83] | Caution with advanced liver or kidney disease; risk for metabolic acidosis with predisposing conditions; avoid abrupt discontinuation |
(3.1-13.8) | ||||
Ondansetron* | Average number of drinks on days alcohol was consumed | If alcoholism onset before age 25, 4.28 relative to 6.9 in placebo(p=0.004) | RCT [84] | Not shown to be beneficial for later-onset alcohol dependence; may prolong QT interval |
Unhealthy alcohol use and the joint commission
Topic | Potential research foci |
---|---|
Screening and assessment | •Is there reason to use more than a single heavy drinking day question to screen for unhealthy alcohol use? |
•Is there a better strategy than screening all admissions? | |
•How should screening be integrated with electronic work flows? | |
•What is the role of newer alcohol consumption biomarkers? | |
•What is the optimal assessment method in the hospital? | |
•What training will hospital-based clinicians require to enhance their skills and confidence in diagnosing alcohol use disorders? | |
•How do patients feel about assessment during hospitalization? | |
Treatment | •What patients are most likely to respond to brief intervention? |
•How can the beneficial effects of brief intervention on alcohol use be increased? | |
•How do we enhance the success of referral? | |
•Does pharmacotherapy for relapse prevention work in this population? | |
•What is the role for joint detection and treatment of other drug and mental health co-morbidities? | |
•Can computerized support enhance treatment? | |
Measuring performance | •What are the effects of brief intervention on other outcomes such as progression of alcohol problems and hospital readmission? |
•What are the most pertinent patient-centered outcomes? | |
•What is the optimal method for assessing the quality of hospital-based SBIRT? |